Edelson Lechtzin's Investigation of Soleno Therapeutics
Edelson Lechtzin LLP is currently conducting an investigation concerning Soleno Therapeutics, Inc. (NASDAQ: SLNO), focusing on potential violations of federal securities laws. This inquiry stems from serious allegations suggesting that Soleno may have provided misleading business information to its investors, impacting their decisions.
Understanding the Investigation
The investigation seeks to uncover whether Soleno's communication and actions regarding its VYKAT XR treatment have misinformed the public and investors. The implications of such statements can be significant, affecting stock prices and investor confidence. If you possess any information that could aid this investigation or have experienced losses related to Soleno, your insights could be invaluable.
About Soleno Therapeutics
Soleno Therapeutics is a biopharmaceutical company committed to developing innovative therapies aimed at treating rare diseases. Their recent product, VYKAT XR, targets hyperphagia symptoms in patients over four years old, particularly those with Prader-Willi syndrome. This focus highlights the firm’s dedication to addressing niche medical needs that often lack robust solutions.
Allegations of Wrongdoing
In March 2025, the FDA authorized the launch of Soleno's VYKAT XR. However, by November, the company faced setbacks, revealing that there was an 8% rate of discontinuation due to side effects related to the drug. Furthermore, a report issued by short-sellers had previously hampered the rollout of this treatment, leading to a significant decrease in Soleno’s stock price by over 26%. This situation has understandably raised concerns among investors.
About Edelson Lechtzin LLP
Edelson Lechtzin LLP is recognized as a national class action law firm with offices located in Pennsylvania and California. They specialize in a variety of legal areas, including securities fraud and antitrust law violations. Their experience in advocating for investors and employees is well-established, and they emphasize consumer protection.
Contact Information for Interested Parties
If you are an investor in Soleno Therapeutics or have pertinent information regarding the investigation, you can reach out directly to the firm. You may contact attorney Eric Lechtzin at 844-563-5550 for assistance. The firm invites all interested individuals to come forward as they gather more information regarding this case.
Frequently Asked Questions
What is the focus of Edelson Lechtzin's investigation?
The investigation focuses on potential violations of securities laws by Soleno Therapeutics due to misleading information about their products.
Who should contact Edelson Lechtzin regarding the investigation?
Investors who have suffered losses related to Soleno Therapeutics, or those with relevant information, are encouraged to reach out.
What is VYKAT XR?
VYKAT XR is a treatment developed by Soleno for hyperphagia in patients with Prader-Willi syndrome.
How has Soleno's stock been affected?
The stock price of Soleno dropped over 26% following disclosures about the discontinuation rate of VYKAT XR and reports from short-sellers.
What type of law does Edelson Lechtzin LLP practice?
Edelson Lechtzin specializes in class action lawsuits, securities fraud, antitrust violations, and more, representing various client interests.
